measuring access to diagnosis and treatment rbm-cmwg july 9, 2009 richard steketee, macepa-path...

19
Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Upload: carson-cheeseman

Post on 15-Jan-2016

215 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Measuring access to diagnosis and treatment

RBM-CMWGJuly 9, 2009

Richard Steketee, MACEPA-PATHRBM-MERG Co-Chair

Page 2: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Measuring access to Dx and Tx

• “If you choose to measure it, you value it”• “If you choose not to measure it, you don’t value it”

• But, not everything needs to be measured and we should first pay attention to:– What we want to do/accomplish– Who is responsible for doing the work– Who needs to measure– Who needs to respond to the data

Page 3: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Measuring access to Dx and Tx

• Information needs at Global, Country, and Local levels differ:– Time and frequency– Precision and consistency of methods, etc.

• Methods should therefore differ based on differing needs– Population-based surveys, routine reporting,

administrative systems, special studies

Page 4: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Measuring access to Dx and Tx

• “Prompt effective treatment of children <5yrs old with fever or malaria”– Prompt = “within 24 hours of illness onset” (or other

definitions)– Effective = “ACT” or “nationally-recommended regimen”

(or other definitions)– Treatment = “full course”? or “any dosing”– Children <5yrs old – ok (but in some places wider age

group?)– Fever or Malaria (but fever ≠ malaria, and this is a

changing relationship as malaria control improves)

Page 5: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Measuring access to Dx and Tx

• RBM-MERG (and many others) recognized that the population based surveys had a real problem:– Surveys had a standard of determining if a child had a fever within

the past 2 weeks and then assessed their access to treatment (home, health care worker, facility)

– So, if the frequency of treatment changes, is this good or bad?

– If the program promotes diagnosis, they should have a lower proportion of febrile children treated (so a decrease would be good)

– If the program promotes treatment of all febrile children, they should try to get a higher proportion treated (so an increase would be good)

Page 6: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

2006-2008 MICS, DHS and MIS compared to previous surveys 2000-2005

• At the Global perspective, the surveys showed essentially no change in the proportion of children with fever receiving malaria treatment

• Countries showing more progress in malaria prevention coverage (ITN and IRS coverage) had a tendency to have lower rates of malaria treatment of children with fever– They were also more likely to be introducing diagnosis

Page 7: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Introduced question on diagnosisinto surveys (DHS, MICS, MIS)

Child with Fever?

Yes

Seen by health worker?

Yes

Finger or heel stick?

Page 8: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

But current question on treatment=

Child with Fever?

Yes

Seen by health worker?

Yes

Finger or heel stick?

Result positive?

Treated?

Drug?

Timing?

Page 9: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Introduced question on diagnosis – can extend to diagnosis + treatment

Child with Fever?

Yes

Seen by health worker?

Yes

Finger or heel stick?

Result positive?

Treated?

Drug?

Timing?

As these are children who have been seen by a health worker, information from routine health facility data and special studies may be particularly helpful

Page 10: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Data on Diagnostics among children with fever

Page 11: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Children <5 yrs with fever

• 3218 children: 843 (28%) with fever in the last 2 weeks– 35% in 12-23 month age group– 30% in rural, 24% in urban

• 64% went to a facility or provider

• 43% took an antimalarial

• 29% took antimalarial within 24hrs of onset

Page 12: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Among the 843 Children <5 yrs with fever in the last 2 weeks

• 64% went to a facility or provider

• 10.9% had finger or heel stick(17% of those seeing a provider)– Male = Female – By Province: range 0% to 29%

(up to ~45% for those seeing a provider)

-- Urban vs Rural: 15.3% vs 9.5%

Page 13: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Children <5 yrs with fever

• 10.9% had finger or heel stickAge: <12m 10.1%

12-23m 7.0%

24-35m 12.4%

36-47m 12.6%

48-59m 15.1%

Quintile: lowest 9.9%

highest 19.5%

Page 14: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

A few additional thoughts

Page 15: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Measuring access to Dx and Tx

• Survey data: – Population-based, national monitoring, relevant to

country and multi-country decision making

• Health worker or Facility routine data:– Only population seeing HW, district monitoring for

management, stock-in/out (note this is a problem that needs immediate response, not a monthly assessment)

• Special study data:– Answering specific questions in access, health worker

performance, etc.

Page 16: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Common challenges assessing Diagnostics and Treatment issues

• Denominator– Child with fever; child seen by health provider; child

with diagnosis; child with positive diagnosis

• Numerator– Child treated with proper drug, in proper time, with full

course

• Diagnosis type– Microscopy, RDT, other diagnostic

• Diagnosis result– Ability to examine Tx based on reported result versus

laboratory documented result

Page 17: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Conclusions

• Measurement of Dx and TX is not easy

• Standards will never be perfect, but they will likely help programs

• Good communication about the choice of standards and their appropriate use in countries will be critical

Page 18: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair

Relevance to RBM-CMWG

• RBM-MERG has done much thinking about this and there is some progress

• A specific link between RBM-MERG and RBM-CMWG (a joint “task force” of a few committed people?) could allow the link between standards of program advice and standards of program monitoring– Produce a white paper on “current and anticipated

needs and approaches to measuring malaria diagnosis and treatment” for both WGs to review?

Page 19: Measuring access to diagnosis and treatment RBM-CMWG July 9, 2009 Richard Steketee, MACEPA-PATH RBM-MERG Co-Chair